Schneeweiss S - Search Results

1

Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations.

Wang SV, Gagne JJ, Glynn RJ, Schneeweiss S. Wang SV, et al. Among authors: schneeweiss s. Epidemiology. 2013 May;24(3):375-8. doi: 10.1097/EDE.0b013e31828ac9cb. Epidemiology. 2013. PMID: 23466528 Free PMC article.

2

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Schneeweiss S, et al. N Engl J Med. 2002 Mar 14;346(11):822-9. doi: 10.1056/NEJMsa003087. N Engl J Med. 2002. PMID: 11893794 Free article.

3

Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Schneeweiss S, et al. CMAJ. 2002 Mar 19;166(6):737-45. CMAJ. 2002. PMID: 11944760 Free PMC article.

4

Clozapine use and risk of diabetes mellitus.

Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Wang PS, et al. Among authors: schneeweiss s. J Clin Psychopharmacol. 2002 Jun;22(3):236-43. doi: 10.1097/00004714-200206000-00002. J Clin Psychopharmacol. 2002. PMID: 12006892

5

Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance.

Schneeweiss S, Maclure M, Soumerai SB, Walker AM, Glynn RJ. Schneeweiss S, et al. J Clin Epidemiol. 2002 Aug;55(8):833-41. doi: 10.1016/s0895-4356(02)00437-7. J Clin Epidemiol. 2002. PMID: 12384199

6

Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.

Avorn J, Benner J, Ford I, Ganz DA, Gaw A, Glynn RJ, Jackson J, Lagaay AM, Schneeweiss S, Walley T, Wang PS; Outcomes Research Working Group and the PROSPER Study Group. Avorn J, et al. Among authors: schneeweiss s. Control Clin Trials. 2002 Dec;23(6):757-73. doi: 10.1016/s0197-2456(02)00228-3. Control Clin Trials. 2002. PMID: 12505250

7

Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.

Duetz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Soumerai SB. Duetz MS, et al. Among authors: schneeweiss s. Clin Ther. 2003 Jan;25(1):273-84. doi: 10.1016/s0149-2918(03)90037-3. Clin Ther. 2003. PMID: 12637126

8

Improved comorbidity adjustment for predicting mortality in Medicare populations.

Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Schneeweiss S, et al. Health Serv Res. 2003 Aug;38(4):1103-20. doi: 10.1111/1475-6773.00165. Health Serv Res. 2003. PMID: 12968819 Free PMC article.

9

Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.

Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Schneeweiss S, et al. Clin Pharmacol Ther. 2003 Oct;74(4):388-400. doi: 10.1016/S0009-9236(03)00227-3. Clin Pharmacol Ther. 2003. PMID: 14534526

10

Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important?

Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Solomon DH, et al. Among authors: schneeweiss s. Am J Med. 2003 Dec 15;115(9):715-20. doi: 10.1016/j.amjmed.2003.08.025. Am J Med. 2003. PMID: 14693324

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

610 results

Search Page